New drug aims to sharpen thinking in Huntington's patients

NCT ID NCT05358821

Completed Symptom relief Sponsor: Supernus Pharmaceuticals, Inc. Source: ClinicalTrials.gov ↗

First seen Jun 24, 2026 · Last updated Jun 26, 2026 · Updated 1 time

Summary

This study tested whether SAGE-718, an experimental oral drug, can improve cognitive function in people with early Huntington's disease. 69 participants took either the drug or a placebo for 28 days. The main goal was to measure changes in thinking skills using a battery of cognitive tests.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: SAGE-718 (oral capsules)
What this could lead to: If successful, this could point toward a treatment to improve thinking and daily functioning in people with early Huntington's disease.
What could go wrong: This is a small, early-phase trial (Phase 2) with only 69 participants. The drug may not show meaningful benefits over placebo, and side effects are possible.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HUNTINGTON DISEASE are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Huntington disease

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

HUNTINGTON DISEASE

Contacts and locations

Locations

Sage Investigational Site

Birmingham, Alabama, 35233, United States
Sage Investigational Site

Los Alamitos, California, 90720, United States
Sage Investigational Site

Englewood, Colorado, 80113, United States
Sage Investigational Site

Washington D.C., District of Columbia, 20057, United States
Sage Investigational Site

Boca Raton, Florida, 33431, United States
Sage Investigational Site

Tampa, Florida, 33602, United States
Sage Investigational Site

Chicago, Illinois, 60612, United States
Sage Investigational Site

Baltimore, Maryland, 21218, United States
Sage Investigational Site

New York, New York, 10027, United States
Sage Investigational Site

Chapel Hill, North Carolina, 27599, United States
Sage Investigational Site

Cincinnati, Ohio, 45221, United States
Sage Investigational Site

Philadelphia, Pennsylvania, 19104, United States
Sage Investigational Site

Houston, Texas, 77030, United States
Sage Investigational Site

Montreal, H2X 3E4, Canada

More trials for these conditions

Other studies related to the condition(s) this trial covers.